In a randomized controlled trial, Tranilast, a potential NLRP3 inflammasome inhibitor, was used as a complementary treatment in combination with standard therapeutic measures (e.g., antivirals and supportive care) in COVID-19 patients (207). The gene discussed is NLRP3; the disease is COVID-19.